Novo Nordisk open to New York listing upgrade, CEO Doustdar tells FT

Novo Nordisk is considering an upgrade to its US listing to provide American investors with direct access to the Danish group's stock. CEO Mike Doustdar informed the FT that he sees clear advantages in this potential move. The company, known for producing Ozempic, is evaluating the benefits of a New York listing upgrade to enhance its accessibility within the US market, reflecting a strategic openness to evolving its financial presence in North America.